Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma-Reference-Cited by-同舟云学术

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Published:2019-10-01 Issue:10 Volume:5 Page:1431
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

O’Reilly Eileen M.¹,Oh Do-Youn²,Dhani Neesha³,Renouf Daniel J.⁴,Lee Myung Ah⁵,Sun Weijing⁶,Fisher George⁷,Hezel Aram⁸,Chang Shao-Chun⁹,Vlahovic Gordana⁹,Takahashi Osamu⁹,Yang Yin⁹,Fitts David¹⁰,Philip Philip Agop¹¹

Affiliation:

1. Gastrointestinal Medical Oncology, David M. Rubenstein Center for Pancreatic Cancer, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York

2. Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

3. Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

4. Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada

5. Department of Oncology, Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea

6. Division of Medical Oncology, University of Kansas Medical Center, Kansas City

7. Department of Medicine–Medical Oncology, Stanford University, Stanford, California

8. Division of Hematology and Oncology, University of Rochester, Rochester, New York

9. AstraZeneca, Gaithersburg, Maryland

10. Independent Biostatistician, Durham, North Carolina

11. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2738420/jamaoncology_oreilly_2019_oi_190043.pdf

Reference45 articles.

1. Pancreatic cancer genetics.;Amundadottir;Int J Biol Sci,2016

2. Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies.;Chiaravalli;Cancer Treat Rev,2017

3. Addressing the challenges of pancreatic cancer: future directions for improving outcomes.;Hidalgo;Pancreatology,2015

4. Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).;Uccello;Curr Oncol,2018

5. Pancreatic ductal adenocarcinoma: from genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.;Fokas;Biochim Biophys Acta,2015

Cited by 469 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis;Modern Pathology;2024-11

3. Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer;Biomedicine & Pharmacotherapy;2024-10

4. Barriers and opportunities in pancreatic cancer immunotherapy;npj Precision Oncology;2024-09-12

5. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma;Journal of Experimental & Clinical Cancer Research;2024-09-11